Is there a link between liraglutide and pancreatitis? A post Hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials

Diabetes Care

Volumn 38, Issue 6, 2015, Pages 1058-1066

  Jensen, Troels M ^a   Saha, Kishore ^b   Steinberg, William M ^c  

^a Novo Nordisk Ltd   (United Kingdom)

^b NOVO NORDISK A S   (Denmark)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; EXENDIN 4; GLIMEPIRIDE; INSULIN GLARGINE; LIRAGLUTIDE; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; TRIACYLGLYCEROL LIPASE; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ACUTE PANCREATITIS; ARTICLE; CHRONIC PANCREATITIS; CONFOUNDING VARIABLE; DRUG EXPOSURE; DRUG FATALITY; HUMAN; INCIDENCE; META ANALYSIS (TOPIC); NEPHROSCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CALCIFICATION; PANCREATITIS; PATIENT INFORMATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW (TOPIC); UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; ACUTE DISEASE; ADULT; AGED; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; FEMALE; MALE; META ANALYSIS; MIDDLE AGED; RISK FACTOR;

ACUTE DISEASE; ADULT; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MIDDLE AGED; PANCREATITIS; PANCREATITIS, CHRONIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SULFONYLUREA COMPOUNDS;

EID: 84944035499     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-1210     Document Type: Article

References (49)

1. Amylin Pharmaceuticals Inc. and Eli Lilly & Company, 2007. Available from http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm126437.pdf. Accessed 22 March 2014.
2. Prescribing information for liraglutide. Available from http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/022341s020lbl.pdf. Accessed 26 March 2014.
3. Questions and answers - safety requirements for Victoza (liraglutide). Available from http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm198543.htm. Accessed June 2014.
4. Prescribing information for sitagliptin. Available from http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/021995s028lbl.pdf. Accessed 26 March 2014.
5. Prescribing information for saxagliptin. Available from http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/022350s011lbl.pdf. Accessed 26 March 2014.
6. Prescribing information for linagliptin. Available from http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/201280s006lbl.pdf. Accessed 26 March 2014.
7. Prescribing information for exenatide twice daily. Available from http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/021773s029s030lbl.pdf. Accessed 26 March 2014.
8. Prescribing information for exenatide once weekly. Available from http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/022200s008lbl.pdf. Accessed 26 March 2014.
9. Novo Nordisk A/S. Victoza [liraglutide] summary of product characteristics [article online], 2012. Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/001026/WC500050017.pdf. Accessed 22 March 2014.
10. Novartis Europharm Ltd. Galvus [vildagliptin] summary of product characteristics [article online], 2012. Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000771/WC500020327.pdf. Accessed 22 March 2014.
11. sanofi-aventis groupe. Lyxumia [lixisenatide] summary of product characteristics. Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002445/WC500140401.pdf. Accessed 22 March 2014.
12. European Medicines Agency. Investigation into GLP-1-based diabetes therapies concluded [article online], 2013. Available from http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2013/07/news-detail-001856.jsp&mid=WC0b01ac058004d5c1. Accessed 22 March 2014.
13. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide- 1-based therapies. Gastroenterology 2011;141: 150-156.
14. Lee PH, Stockton MD, Franks AS. Acute pancreatitis associated with liraglutide. Ann Pharmacother 2011;45:e22.
15. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.
16. Meier JJ, Nauck MA. Risk of pancreatitis in patients treated with incretin-based therapies. Diabetologia 2014;57:1320-1324.
17. Franks AS, Lee PH, George CM. Pancreatitis: a potential complication of liraglutide? Ann Pharmacother 2012;46:1547-1553.
18. Raschi E, Piccinni C, Poluzzi E, Marchesini G, De Ponti F. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol 2013;50:569-577.
19. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1- based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013;173:534-539.
20. Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract 2012;98:271-284.
21. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010; 33:2349-2354.
22. Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011;27(Suppl. 3): 57-64.
23. Li L, Shen J, BalaMM, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and nonrandomised studies. BMJ 2014;348:g2366.
24. Ryder REJ, Thong KY, Blann AD, et al.; ABCD Nationwide Liraglutide Audit Contributors. Liraglutide pancreatitis: The ABCD nationwide liraglutide audit. Br J Diabetes Vasc Dis 2013;13: 253-259.
25. Kahn SE. Incretin therapy and islet pathology: a time for caution. Diabetes 2013;62:2178- 2180.
26. Nauck MA. A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks. Diabetes Care 2013;36:2126-2132.
27. Bonner-Weir S, In't Veld PA, Weir GC. Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies. Diabetes Obes Metab 2014;16:661-666.
28. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugsdFDA and EMA assessment. N Engl J Med 2014;370:794-797.
29. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria, R Foundation for Statistical Computing, 2012. Available from http://www.R-project.org. Accessed 22 March 2014.
30. Banks PA, Bollen TL, Dervenis C, et al.; Acute Pancreatitis Classification Working Group. Classification of acute pancreatitisd2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013; 62:102-111.
31. Forsmark CE. Chronic pancreatitis. In Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 9th ed. Feldman M, Friedman L, Brand L, Eds. Philadelphia, Saunders/Elsevier, 2010, p. 998-999.
32. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009;32:834-838.
33. Girman CJ, Kou TD, Cai B, et al. Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obes Metab 2010;12:766- 771.
34. Gonzalez-Perez A, Schlienger RG, Rodŕiguez LA. Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a populationbased cohort study. Diabetes Care 2010;33: 2580-2585.
35. Steinberg WM. Comment: acute pancreatitis associated with liraglutide. Ann Pharmacother 2011;45:1169.
36. Steinberg WM, Rosenstock J, DeVries JH, Thomsen AB, Svendsen CB, Wadden TA. Elevated serum lipase activity in adults with type 2 diabetes and no gastrointestinal symptoms (Abstract). Gastroenterology 2012;142(Suppl. 1): S93-S94.
37. Steinberg WM, DeVries JH, Wadden TA, Jensen CB, Svendsen CB, Rosenstock J. Longitudinal monitoring of lipase and amylase in adults with type 2 diabetes and obesity: evidence from two phase 3 randomized clinical trials with once daily GLP-1 analog liraglutide (Abstract). Gastroenterology 2012;142(Suppl. 1):S850-S851.
38. Lando HM, Alattar M, Dua AP. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting. Endocr Pract 2012;18:472-477.
39. Malloy J, Gurney K, Shan K, Yan P, Chen S. Increased variability and abnormalities in pancreatic enzyme concentrations in otherwise asymptomatic subjects with type 2 diabetes. Diabetes Metab Syndr Obes 2012;5:419-424.
40. Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol 2007;5:648-661; quiz 644.
41. Butler PC, Elashoff M, Elashoff R, Gale EA. A critical analysis of the clinical use of incretinbased therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125.
42. Tenner S, Steinberg WM. Acute pancreatitis. In Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 9th ed. Feldman M, Friedman L, Brand L, Eds. Philadelphia, Saunders/Elsevier, 2010, p. 963-964.
43. Gourdy P, Penfornis A, Charpentier G, et al. Effectiveness and tolerability with liraglutide among patients with type 2 diabetes. 1-year data from EVIDENCE: a 2-year, prospective, follow up, post-marketing study. Poster presented at the 49th Annual Meeting of the European Association for the Study of Diabetes, 27 September 2013, Barcelona, Spain. Available from http://www.easdvirtualmeeting.org/resources/6203. Accessed 26 March 2014.
44. Gourdy P, Penfornis A, Charpentier G, et al. Effectiveness and persistence with liraglutide among patients with type 2 diabetes. One year data from EVIDENCE: a 2-year, prospective, follow up, post-marketing study (Abstract). Diabetologia 2013;56(Suppl. 1):S369.
45. Funch D, Gydesen H, Tornøe K, Major- Pedersen A, Chan KA. A prospective, claimsbased assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. Diabetes Obes Metab 2014;16:273-275.
46. Marso SP, Poulter NR, Nissen SE, et al. Design of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial. Am Heart J 2013;166: 823-830.
47. White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-1335.
48. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326.
49. Jensen TM, Saha K, Steinberg WM. Assessment of acute pancreatitis in liraglutide type 2 diabetes trials. Pancreas 2012;41:1370- 1371.